^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    decitabine

    i
    Company:
    Generic mfg.
    Drug class:
    DNMT inhibitor
    Related drugs:
    Apply
    IMGN632 as Monotherapy or With Venetoclax and/or Azacitidine for Participants With CD123-Positive Acute Myeloid Leukemia (IMGN632-0802) (NCT04086264)
    Phase 1/2
    AbbVie
    Active, not recruiting
    Last update posted :
    02/24/2025
    Initiation :
    11/06/2019
    Primary completion :
    02/01/2027
    Completion :
    02/01/2027
    IL3RA
    |
    CD123 positive • IL3RA positive
    |
    Venclexta (venetoclax) • azacitidine • decitabine • pivekimab sunirine (PVEK)
    Testing a New Chemotherapy Drug, KRT-232 (AMG-232) in Combination With Decitabine and Venetoclax in Patients With Acute Myeloid Leukemia (NCT03041688)
    Phase 1
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/24/2025
    Initiation :
    02/08/2018
    Primary completion :
    06/30/2026
    Completion :
    06/30/2026
    TP53 • CD4
    |
    TP53 mutation • Chr del(17p) • TP53 wild-type
    |
    Venclexta (venetoclax) • azacitidine • decitabine • navtemadlin (KRT-232)
    Ipilimumab and Decitabine in Treating Patients With Relapsed or Refractory Myelodysplastic Syndrome or Acute Myeloid Leukemia (NCT02890329)
    Phase 1
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/21/2025
    Initiation :
    09/05/2017
    Primary completion :
    10/24/2022
    Completion :
    08/19/2025
    CD4
    |
    High ALC
    |
    Yervoy (ipilimumab) • azacitidine • decitabine • CS1002 (ipilimumab biosimilar)
    Navitoclax in Relapsed or Refractory High-Risk Myelodysplastic Syndrome (22P.205) (NCT05564650)
    Phase 1/2
    Thomas Jefferson University
    Active, not recruiting
    Last update posted :
    02/11/2025
    Initiation :
    01/12/2023
    Primary completion :
    04/10/2026
    Completion :
    04/10/2026
    BCL2
    |
    BCL2 expression
    |
    Venclexta (venetoclax) • azacitidine • decitabine • navitoclax (ABT 263)
    Clinical Trial With Local Decitabine Treatment of HPV-Induced VIN Grade 2/3 (DelVIN) (NCT05717621)
    Phase 1
    ViMREX GmbH
    Completed
    Last update posted :
    02/11/2025
    Initiation :
    03/28/2023
    Primary completion :
    01/17/2025
    Completion :
    01/17/2025
    CDKN2A
    |
    CDKN2A overexpression
    |
    decitabine
    Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome (NCI-2018-01789) (NCT03661307)
    Phase 1/2
    M.D. Anderson Cancer Center
    Recruiting
    Last update posted :
    02/10/2025
    Initiation :
    10/31/2018
    Primary completion :
    01/01/2026
    Completion :
    01/01/2026
    TP53 • FLT3
    |
    TP53 mutation • FLT3-ITD mutation • FLT3 mutation • TP53 deletion
    |
    Venclexta (venetoclax) • azacitidine • Vanflyta (quizartinib) • decitabine
    Trial Testing Safety of IL-21 NK Cells for Induction of R/R AML (NCT04220684)
    Phase 1
    Sumithira Vasu
    Active, not recruiting
    Last update posted :
    02/07/2025
    Initiation :
    06/11/2020
    Primary completion :
    10/22/2024
    Completion :
    12/31/2025
    IL21
    |
    cytarabine • azacitidine • decitabine • fludarabine IV • SAR445419
    Neoadjuvant Pembrolizumab + Decitabine Followed by Std Neoadj Chemo for Locally Advanced HER2- Breast Ca (NCT02957968)
    Phase 2
    Virginia Commonwealth University
    Active, not recruiting
    Last update posted :
    11/11/2024
    Initiation :
    01/24/2017
    Primary completion :
    08/04/2022
    Completion :
    02/28/2025
    HER-2 • ER • PGR
    |
    HR positive • HER-2 negative • HER-2 negative + HR negative
    |
    Keytruda (pembrolizumab) • carboplatin • doxorubicin hydrochloride • azacitidine • albumin-bound paclitaxel • cyclophosphamide • decitabine • cyclophosphamide intravenous
    Chidamide+Decitabine Plus Anti-PD-1 Antibody for Patients With R/R cHL Who Are Transplant-ineligible or Refused Transplant. (NCT06563778)
    Phase 2
    Chinese PLA General Hospital
    Not yet recruiting
    Last update posted :
    08/21/2024
    Initiation :
    09/01/2024
    Primary completion :
    09/01/2026
    Completion :
    09/01/2028
    PD-1
    |
    decitabine • Adcetris (brentuximab vedotin) • Epidaza (chidamide) • bendamustine
    Gene-Modified T Cells With or Without Decitabine in Treating Patients With Advanced Malignancies Expressing NY-ESO-1 (NCT02650986)
    Phase 1/2
    Roswell Park Cancer Institute
    Active, not recruiting
    Last update posted :
    06/13/2024
    Initiation :
    07/14/2017
    Primary completion :
    03/04/2021
    Completion :
    07/14/2032
    BRAF • CTAG1B
    |
    BRAF mutation
    |
    azacitidine • cyclophosphamide • decitabine • cyclophosphamide intravenous
    Chidamide+Decitabine Plus Anti-PD-1 Antibody in PD-1 Inhibitor Failed Patients With Classical Hodgkin Lymphoma. (NCT06393361)
    Phase 2
    Chinese PLA General Hospital
    Recruiting
    Last update posted :
    06/11/2024
    Initiation :
    06/01/2024
    Primary completion :
    06/01/2026
    Completion :
    06/01/2027
    PD-1
    |
    carboplatin • gemcitabine • ifosfamide • etoposide IV • decitabine • pegylated liposomal doxorubicin • Adcetris (brentuximab vedotin) • Epidaza (chidamide)
    Venetoclax + Decitabine vs. "7+3" Induction Chemotherapy in Young AML (NCT05177731)
    Phase 3
    Chen Suning
    Active, not recruiting
    Last update posted :
    06/07/2024
    Initiation :
    03/01/2022
    Primary completion :
    02/28/2024
    Completion :
    12/31/2024
    BCL2
    |
    Venclexta (venetoclax) • cytarabine • Xospata (gilteritinib) • decitabine • idarubicin hydrochloride
    Testing Nivolumab in Combination With Decitabine and Venetoclax in Patients With Newly Diagnosed TP53 Gene Mutated Acute Myeloid Leukemia (NCT04277442)
    Phase 1
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    06/06/2024
    Initiation :
    03/11/2020
    Primary completion :
    09/06/2022
    Completion :
    06/04/2025
    TP53
    |
    TP53 mutation
    |
    Opdivo (nivolumab) • Venclexta (venetoclax) • azacitidine • decitabine • ABP 206 (nivolumab biosimilar) • CMAB 819 (nivolumab biosimilar)
    Decitabine and Venetoclax Treatment as Maintenance Therapy in Patients Post Allograft Stem Cell Transplant (NCT06129734)
    Phase 1/2
    Benjamin Tomlinson
    Not yet recruiting
    Last update posted :
    06/06/2024
    Initiation :
    10/01/2024
    Primary completion :
    12/27/2024
    Completion :
    12/31/2025
    BCL2
    |
    Venclexta (venetoclax) • decitabine
    Ruxolitinib Phosphate and Decitabine in Treating Patients With Relapsed or Refractory or Post Myeloproliferative Acute Myeloid Leukemia (NCT02257138)
    Phase 1/2
    M.D. Anderson Cancer Center
    Completed
    Last update posted :
    05/08/2024
    Initiation :
    02/12/2015
    Primary completion :
    03/19/2021
    Completion :
    03/19/2021
    JAK2
    |
    JAK2 mutation
    |
    azacitidine • Jakafi (ruxolitinib) • decitabine
    Decitabine, Venetoclax, and Ponatinib for the Treatment of Philadelphia Chromosome-Positive Acute Myeloid Leukemia or Myeloid Blast Phase or Accelerated Phase Chronic Myelogenous Leukemia (NCT04188405)
    Phase 2
    M.D. Anderson Cancer Center
    Active, not recruiting
    Last update posted :
    05/02/2024
    Initiation :
    05/17/2020
    Primary completion :
    09/01/2024
    Completion :
    09/01/2024
    ABL1 • BCR • BCL2
    |
    BCL2 expression
    |
    Venclexta (venetoclax) • Iclusig (ponatinib) • azacitidine • decitabine
    NKX101, Intravenous Allogeneic CAR NK Cells, in Adults With AML or MDS (NKX101-101) (NCT04623944)
    Phase 1
    Nkarta Inc.
    Active, not recruiting
    Last update posted :
    04/09/2024
    Initiation :
    09/21/2020
    Primary completion :
    07/01/2024
    Completion :
    07/01/2039
    FLT3
    |
    FLT3 mutation
    |
    cytarabine • cyclophosphamide • decitabine • fludarabine IV • NKX101
    Rational EpigenetiC Immunotherapy for SEcond Line Therapy in Patients With NSCLC: PRECISE Trial (NCT02664181)
    Phase 2
    Case Comprehensive Cancer Center
    Active, not recruiting
    Last update posted :
    04/09/2024
    Initiation :
    06/06/2017
    Primary completion :
    07/02/2019
    Completion :
    08/15/2024
    EGFR • ALK
    |
    Opdivo (nivolumab) • decitabine
    Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia (NCT03418038)
    Phase 2
    Mayo Clinic
    Recruiting
    Last update posted :
    04/02/2024
    Initiation :
    03/23/2018
    Primary completion :
    12/01/2025
    Completion :
    03/01/2026
    IDH1 • BCL2 • IDH2 • DNMT3A • SF3B1 • TET2 • SRSF2 • U2AF1 • CD4 • ZRSR2
    |
    IDH2 mutation • DNMT3A mutation • TET2 mutation • SF3B1 mutation • EZH2 mutation • SRSF2 mutation • U2AF1 mutation
    |
    cisplatin • carboplatin • gemcitabine • Rituxan (rituximab) • cytarabine • cyclophosphamide • ifosfamide • oxaliplatin • etoposide IV • decitabine • dexamethasone • Truxima (rituximab-abbs) • Riabni (rituximab-arrx) • Delito (rituximab biosimilar) • Hemady (dexamethasone tablets) • GB241 (rituximab biosimilar) • JHL1101 (rituximab biosimilar) • Mabtas (rituximab biosimilar) • Novex (rituximab biosimilar) • SIBP-02 (rituximab biosimilar) • Starasid (cytarabine ocfosfate) • cyclophosphamide intravenous • dexamethasone injection
    5-Azacitidine and Decitabine Epigenetic Therapy for Myeloid Malignancies (NCT04187703)
    Phase 1
    Benjamin Tomlinson
    Recruiting
    Last update posted :
    03/11/2024
    Initiation :
    11/16/2020
    Primary completion :
    12/01/2024
    Completion :
    12/01/2025
    ABL1 • BCR • CD14 • DCK • DNMT1 • ITGAM • NT5C
    |
    Chr del(5q)
    |
    azacitidine • decitabine
    Pevonedistat and Decitabine in Treating Patients With High Risk Acute Myeloid Leukemia (NCT03009240)
    Phase 1
    City of Hope Medical Center
    Active, not recruiting
    Last update posted :
    03/08/2024
    Initiation :
    08/21/2017
    Primary completion :
    12/15/2024
    Completion :
    12/15/2024
    MIR155 • NFKB1
    |
    miR-155 expression • NFKB1 expression
    |
    decitabine • pevonedistat (MLN4924)
    Prolonged Ultra Low-dose Decitabine Plus Venetoclax for Primary Diagnosed Elderly AMLK/MDS (NCT06046313)
    Phase 2
    First Affiliated Hospital of Zhejiang University
    Recruiting
    Last update posted :
    03/05/2024
    Initiation :
    10/19/2023
    Primary completion :
    10/19/2025
    Completion :
    10/19/2026
    BCL2
    |
    Venclexta (venetoclax) • decitabine
    Decitabine-primed Tandem CD19/CD20 CAR T Cells Treatment in r/r B-NHL (NCT04697940)
    Phase 1/2
    Han weidong
    Recruiting
    Last update posted :
    02/07/2024
    Initiation :
    12/15/2020
    Primary completion :
    12/30/2024
    Completion :
    12/30/2025
    BCL2 • CCND1 • BCL6
    |
    Chr t(11;14) • CCND1 overexpression • BCL6 rearrangement • Chr t(11;14)(q13;q32) • BCL2 rearrangement • CD20 negative
    |
    cyclophosphamide • decitabine • fludarabine IV
    Pembrolizumab in Combination With Decitabine and Hypofractionated Index Lesion Radiation in Pediatrics and Young Adults (NCT03445858)
    Phase 1
    Children's Hospital Medical Center, Cincinnati
    Active, not recruiting
    Last update posted :
    01/25/2024
    Initiation :
    02/12/2018
    Primary completion :
    06/15/2024
    Completion :
    01/12/2025
    PD-L1
    |
    Keytruda (pembrolizumab) • decitabine
    Venetoclax and Decitabine in Treating Participants With Relapsed/Refractory Acute Myeloid Leukemia or Relapsed High-Risk Myelodysplastic Syndrome (DEC10-VEN) (NCT03404193)
    Phase 2
    M.D. Anderson Cancer Center
    Active, not recruiting
    Last update posted :
    01/05/2024
    Initiation :
    01/18/2018
    Primary completion :
    12/31/2024
    Completion :
    12/31/2024
    TP53
    |
    TP53 mutation • TP53 deletion
    |
    Venclexta (venetoclax) • azacitidine • decitabine
    Pembrolizumab and Decitabine With or Without Venetoclax in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome That Is Newly-Diagnosed, Recurrent, or Refractory (NCT03969446)
    Phase 1
    City of Hope Medical Center
    Recruiting
    Last update posted :
    01/03/2024
    Initiation :
    05/04/2020
    Primary completion :
    11/04/2025
    Completion :
    11/04/2025
    PD-L1 • PD-1 • PD-L2
    |
    Keytruda (pembrolizumab) • Venclexta (venetoclax) • decitabine
    Combination Salvage Therapy With Venetoclax and Decitabine in Relapsed/Refractory AML (VenSwitch) (NCT06156579)
    Phase 2
    University Hospital Tuebingen
    Recruiting
    Last update posted :
    12/05/2023
    Initiation :
    11/04/2023
    Primary completion :
    12/04/2024
    Completion :
    03/04/2025
    BCL2
    |
    Venclexta (venetoclax) • decitabine
    Dendritic Cell/AML Fusion Cell Vaccine Following Allogeneic Transplantation in AML Patients (NCT03679650)
    Phase 1
    Beth Israel Deaconess Medical Center
    Recruiting
    Last update posted :
    11/24/2023
    Initiation :
    10/11/2018
    Primary completion :
    08/31/2024
    Completion :
    08/31/2026
    HLA-DRB1
    |
    decitabine
    Azacitidine With or Without Nivolumab or Midostaurin, or Decitabine and Cytarabine Alone in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome (NCT03092674)
    Phase 2/3
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    11/10/2023
    Initiation :
    02/02/2018
    Primary completion :
    08/01/2023
    Completion :
    10/29/2024
    FLT3
    |
    Opdivo (nivolumab) • cytarabine • azacitidine • midostaurin • decitabine • ABP 206 (nivolumab biosimilar) • Starasid (cytarabine ocfosfate)
    Efficacy and Safety Evaluation of IBI188 in Combination With Demethylating Agents in Treatment of Patients With Acute Myeloid Leukemia (NCT04485052)
    Phase 1/2
    Innovent Biologics (Suzhou) Co. Ltd.
    Suspended
    Last update posted :
    10/23/2023
    Initiation :
    09/25/2020
    Primary completion :
    06/30/2024
    Completion :
    12/31/2024
    ABL1 • BCR
    |
    azacitidine • decitabine • letaplimab (IBI188)
    Comparison of the Efficacy and Safety of Venetoclax in Combination With 3 Days Decitabine (DEC3-VEN) vs. Venetoclax in Combination With Azacitidine (VIALE-A) in the Treatment of Elderly Patients or Unfit, New-diagnosis Acute Myeloid Leukemia Patients (NCT06073730)
    Phase 3
    The Second Affiliated Hospital of Kunming Medic...
    Not yet recruiting
    Last update posted :
    10/09/2023
    Initiation :
    11/01/2023
    Primary completion :
    11/01/2024
    Completion :
    11/01/2025
    RUNX1
    |
    Venclexta (venetoclax) • sorafenib • azacitidine • decitabine
    Study of Venetoclax in Combination With Decitabine in Subjects With Acute Myeloid Leukemia (NCT03844815)
    Phase 1
    University of Chicago
    Recruiting
    Last update posted :
    08/29/2023
    Initiation :
    11/18/2019
    Primary completion :
    06/10/2024
    Completion :
    06/10/2025
    TP53
    |
    TP53 mutation
    |
    Venclexta (venetoclax) • decitabine
    A Clinical Trial of BP1002 in Patients With Refractory/Relapsed Acute Myeloid Leukemia (AML) (NCT05190471)
    Phase 1
    Bio-Path Holdings, Inc.
    Recruiting
    Last update posted :
    08/21/2023
    Initiation :
    08/16/2022
    Primary completion :
    03/01/2024
    Completion :
    09/01/2024
    BCL2
    |
    decitabine • BP1002
    Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia (E2906) (NCT02085408)
    Phase 3
    ECOG-ACRIN Cancer Research Group
    Active, not recruiting
    Last update posted :
    06/30/2023
    Initiation :
    02/04/2011
    Primary completion :
    02/22/2021
    Completion :
    10/01/2024
    HLA-DRB1 • HLA-B • HLA-C
    |
    cytarabine • decitabine • daunorubicin • clofarabine
    Talazoparib for Cohesin-Mutated AML and MDS With Excess Blasts (NCT03974217)
    Phase 1
    Dana-Farber Cancer Institute
    Recruiting
    Last update posted :
    06/27/2023
    Initiation :
    08/01/2019
    Primary completion :
    12/31/2024
    Completion :
    06/01/2025
    TMB • FLT3 • IDH1 • IDH2 • STAG2 • RAD21 • SMC1A • SMC3
    |
    STAG2 mutation
    |
    Talzenna (talazoparib) • decitabine • hydroxyurea
    Venetoclax+HMA+Aclarubicin Versus Venetoclax+HMA in Treatment-Naive Elderly Patients With AML (NCT05264883)
    Phase 3
    The First Affiliated Hospital with Nanjing Medi...
    Recruiting
    Last update posted :
    05/29/2023
    Initiation :
    03/01/2021
    Primary completion :
    06/28/2023
    Completion :
    02/28/2025
    BCL2
    |
    Venclexta (venetoclax) • azacitidine • decitabine • aclarubicin
    Salsalate, Venetoclax, and Decitabine or Azacitidine for the Treatment of Acute Myeloid Leukemia or Advanced Myelodysplasia/Myeloproliferative Disease (NCT04146038)
    Phase 2
    Rutgers, The State University of New Jersey
    Completed
    Last update posted :
    05/24/2023
    Initiation :
    10/26/2020
    Primary completion :
    10/25/2021
    Completion :
    10/25/2022
    TP53
    |
    TP53 mutation
    |
    Venclexta (venetoclax) • azacitidine • decitabine
    A Pilot Study to Evaluate the Feasibility of Post-Hematopoietic Stem Cell Transplant Prophylaxis With Decitabine Combined With Filgrastim for Children and Young Adults With AML, MDS and Related Myeloid Malignancies (MORE) (NCT05796570)
    Phase 2
    Franziska Wachter
    Recruiting
    Last update posted :
    04/20/2023
    Initiation :
    04/19/2023
    Primary completion :
    09/01/2026
    Completion :
    09/01/2029
    RUNX1 • ETV6 • DDX41 • GATA2 • ANKRD26
    |
    RUNX1 mutation • DDX41 mutation • GATA2 mutation • ETV6 mutation
    |
    decitabine • Neupogen (filgrastim)